Stem cell therapy reverses Type 1 diabetes in mice
Analysis based on 6 articles · First reported Aug 14, 2026 · Last updated Sep 01, 2026
The breakthrough could significantly impact the diabetes treatment market, potentially reducing reliance on lifelong insulin therapy and opening new avenues for regenerative medicine. Biotech and pharmaceutical companies focused on diabetes and stem cell therapies may see increased investor interest and valuation.
Researchers at the Medical University of South Carolina, led by Wang Jun, developed an experimental stem cell therapy that reversed newly diagnosed Type 1 diabetes in mice. The therapy uses adult stem cells derived from donated umbilical cords to reprogram the immune system, increasing protective T-regulatory cells and reducing attacking cells, thereby protecting insulin-producing cells. The findings were published in the journal Molecular Therapy on July 1, 2026. The United States — National Institutes of Health has approved a human trial for 60 participants aged 18 to 40 within six months of diagnosis, scheduled to begin in February 2027. This approach addresses the root cause of Type 1 diabetes—immune system dysfunction—rather than just managing blood sugar.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard